Prof. Atul Deodhar (Oregon Health & Science University, Portland, OR, USA) kindly took the time to discuss the 3-yr interim health-related quality of life (HRQoL) data from the phase 2b BE AGILE study (NCT02963506) and its open-label extension (NCT03355573) investigating bimekizumab in ankylosing spondylitis.
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘Bimekizumab Shows Sustained and Meaningful Long-Term Improvements in Health-Related Quality of Life in Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study’ (ABSTRACT NUMBER: 0922) was presented at the ACR Convergence, 5-9 November 2021.
Questions
- Could you tell us a little about bimekizumab and its mechanism of action? (0:14)
- What have previous phase 2 studies with bimekizumab demonstrated and what were the aims of the current analysis? (0:48)
- Could you tell us about the design of the current analysis and the overall findings? (1:33)
Disclosures: Prof. Atul Deodhar has been a consultant/ advisory board member for AbbVie, Amgen, Aurinia, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Glaxo Smith & Kline, Janssen, Moonlake, Novartis, Pfizer and UCB, and received research grants from AbbVie, Eli Lilly, Glaxo Smith & Kline, Novartis, Pfizer and UCB.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
